Loading...
Keywords
Last Name
Institution

Connection

Search Results to Alan S. Gamis

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Gamis, Alan

PropertyValue
keywords Supportive care
research overview Dr. Gamis' research expertise is in the design and development of multi-institutional clinical trials in childhood cancer, specifically in AML. He is a board certified Pediatric Hematologist/Oncologist and continue to care for patients with cancer in a large children's cancer center. He also trained as an Epidemiologist receiving an MPH in 1991 as a foundation for clinical trial development. He has been active in AML research activities in the Children's Oncology Group since 1993, first serving on several COG clinical trial committees (AML, Neuroblastoma, Hodgkin’s, Stem Cell Transplant, Epidemiology, & Supportive Care/Nursing), then chairing two large clinical trials. The first was the phase III trial COG A2971 - Treatment of Children with Down’s Syndrome and AML, MDS, and Transient Myeloproliferative Disorder, from 1996-2004.This was followed by a second national Phase III trial, COG-AAML0531- Phase III Randomized Trial of Gemtuzumab Combined with Conventional Chemotherapy for de novo Acute Myeloid Leukemia in Children, from 2004 until the present. Dr. Gamis has served as a member of the COG Myeloid Scientific Disease Committee since 1996 and served as Chair of the committee from 2007-2013 overseeing all aspects of Myeloid Leukemia research (design, implementation, analysis, and strategic planning) during which time we designed and developed numerous clinical trials in childhood AML. He has also served on the COG Epidemiology Steering Committee from 1992-1995 and the COG Stem Cell Transplant Steering Committee from 2002 to 2010. He was a founding member of the Pediatric Blood and Marrow Transplant Consortium beginning in 1992 ultimately serving as its Chair from 1999-2004 during which time he led the successful attainment of the UO1 NHLBI grant as an original PI of a clinical core center of the Bone Marrow Transplant Clinical Trials Network (BMT CTN). During this time he successfully joined the PBMTC with the COG through the NIH grant BAA-RM-04-23 grant, Re-engineering the Clinical Research Enterprise: Feasibility of Integrating and Expanding Clinical Research Networks, from 2004-2008. Locally, as the Director of the Children's Mercy Cancer Center, Dr. Gamis oversee all clinical and research activities related to cancer care and successfully oversaw the program's expansion, program development and ultimately consortium institutional partnership with the NCI-designated University of Kansas Cancer Center.

One or more keywords matched the following items that are connected to Gamis, Alan

Item TypeName
Concept Critical Care
Concept Palliative Care
Concept Patient Acceptance of Health Care
Concept Intensive Care Units, Pediatric
Concept Health Care Surveys
Academic Article Acute acetone intoxication in a pediatric patient.
Academic Article Oral care with vancomycin paste for reduction in incidence of alpha-hemolytic streptococcal sepsis.
Academic Article Surveys: a tool to provoke thought and identify areas of need.
Academic Article International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia.
Academic Article Allogeneic marrow transplantation in children with acute leukemia: careful comparison with chemotherapy alternatives required.
Academic Article Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group.
Academic Article Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group.
Academic Article Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group.
Academic Article Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group.
Academic Article Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report.

Search Criteria
  • Supportive
  • care